Literature DB >> 9250148

The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements.

S Pittaluga1, I Wlodarska, K Pulford, E Campo, S W Morris, H Van den Berghe, C De Wolf-Peeters.   

Abstract

Anaplastic large cell lymphoma (ALCL) is a heterogeneous group of diseases by morphology, phenotype, genotype, and clinical presentation. Using a new monoclonal antibody (ALK1) that recognizes the native anaplastic lymphoma kinase (ALK) protein as well as the fusion product of the t(2;5)(p23;q35), nucleophosmin (NPM)/ALK, we investigated for ALK expression cases diagnosed as ALCL as well as lympho-proliferative disorders possessing overlapping features with ALCL. Thirteen cases showed cytoplasmic staining of the neoplastic cells. These cases were characterized by a fairly uniform morphology and occurred in children and young adults as a systemic disease. All other cases comprising T or null ALCL (17 cases), B ALCL (8 cases), Hodgkin's disease (HD) (15 cases), HD-like ALCL (23 cases), and lymphomatoid papulosis (9 cases), were negative for ALK expression. Translocation t(2;5)(p23;q35) was found by classical cytogenetics or interphase fluorescence in situ hybridization in 8 of the ALK1-positive cases and by reverse transcription-polymerase chain reaction in 1 other case. Two additional ALK1-positive cases with an abnormal karyotype, but without t(2;5)(p23;q35), showed by fluorescence in situ hybridization analysis a cryptic NPM/ALK gene fusion caused by an insertion of ALK near NPM in one case and a translocation of ALK to 2q35 as a result of an indiscernible inv(2)(p23q35) in the other. The latter variant translocation points to a localization of an unknown gene at 2q35 that, like NPM, might deregulate ALK and be involved in the pathogenesis of ALCL. In summary, immunohistochemistry with ALK1 antibody allows the identification of a distinct subgroup within the ALCL of T or null phenotype that is associated with 2p23 abnormalities and lacks the marked histological pleomorphism described in ALCL in general. Whereas immunostaining is the most sensitive method to identify this group, it does not help to additionally clarify the relationship among ALCL, HD, and HD-like ALCL.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9250148      PMCID: PMC1858018     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  42 in total

1.  A novel variant translocation t(2;13) (p23;q34) in Ki-1 large cell anaplastic lymphoma.

Authors:  L Sainati; A Montaldi; M Stella; M C Putti; L Zanesco; G Basso
Journal:  Br J Haematol       Date:  1990-08       Impact factor: 6.998

2.  Detection of the t(2;5)(p23;q35) and NPM-ALK fusion in non-Hodgkin's lymphoma by two-color fluorescence in situ hybridization.

Authors:  P Mathew; W G Sanger; D D Weisenburger; M Valentine; V Valentine; D Pickering; C Higgins; M Hess; X Cui; D K Srivastava; S W Morris
Journal:  Blood       Date:  1997-03-01       Impact factor: 22.113

3.  Ki-1 positive large cell lymphoma. A morphologic and immunologic study of 19 cases.

Authors:  B A Agnarsson; M E Kadin
Journal:  Am J Surg Pathol       Date:  1988-04       Impact factor: 6.394

4.  A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis.

Authors:  Y Kaneko; G Frizzera; S Edamura; N Maseki; M Sakurai; Y Komada; M Sakurai; H Tanaka; M Sasaki; T Suchi
Journal:  Blood       Date:  1989-02-15       Impact factor: 22.113

5.  CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35.

Authors:  D Y Mason; C Bastard; R Rimokh; N Dastugue; J L Huret; U Kristoffersson; J P Magaud; C Nezelof; H Tilly; J P Vannier
Journal:  Br J Haematol       Date:  1990-02       Impact factor: 6.998

6.  Ki-1-positive large cell lymphoma. A clinicopathologic study of 41 cases.

Authors:  A Chott; K Kaserer; I Augustin; M Vesely; R Heinz; W Oehlinger; H Hanak; T Radaszkiewicz
Journal:  Am J Surg Pathol       Date:  1990-05       Impact factor: 6.394

7.  Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma.

Authors:  G Pallesen; S J Hamilton-Dutoit
Journal:  Am J Pathol       Date:  1988-12       Impact factor: 4.307

8.  Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1 + with a high content of reactive histiocytes).

Authors:  S Pileri; B Falini; G Delsol; H Stein; P Baglioni; S Poggi; M F Martelli; M T Rivano; D Y Mason; A G Stansfeld
Journal:  Histopathology       Date:  1990-04       Impact factor: 5.087

9.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.

Authors:  H Stein; D Y Mason; J Gerdes; N O'Connor; J Wainscoat; G Pallesen; K Gatter; B Falini; G Delsol; H Lemke
Journal:  Blood       Date:  1985-10       Impact factor: 22.113

10.  Anaplastic large cell lymphoma, CD30/Ki-1 positive, expressing the CD15/Leu-M1 antigen. Immunohistochemical and morphological relationships to Hodgkin's disease.

Authors:  R Rosso; M Paulli; U Magrini; S Kindl; E Boveri; G Volpato; S Poggi; P Baglioni; S Pileri
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990
View more
  16 in total

1.  The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells.

Authors:  B Maes; V Vanhentenrijk; I Wlodarska; J Cools; B Peeters; P Marynen; C de Wolf-Peeters
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

2.  TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.

Authors:  B Lawrence; A Perez-Atayde; M K Hibbard; B P Rubin; P Dal Cin; J L Pinkus; G S Pinkus; S Xiao; E S Yi; C D Fletcher; J A Fletcher
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

3.  ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35).

Authors:  G W Colleoni; J A Bridge; B Garicochea; J Liu; D A Filippa; M Ladanyi
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

4.  High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma.

Authors:  R Rust; G Harms; T Blokzijl; M Boot; A Diepstra; J Kluiver; L Visser; S-C Peh; M Lim; W A Kamps; S Poppema; A van den Berg
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

5.  ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum.

Authors:  B Falini; B Bigerna; M Fizzotti; K Pulford; S A Pileri; G Delsol; A Carbone; M Paulli; U Magrini; F Menestrina; R Giardini; S Pilotti; A Mezzelani; B Ugolini; M Billi; A Pucciarini; R Pacini; P G Pelicci; L Flenghi
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

6.  Implant-associated anaplastic large cell lymphoma of the breast: Insight into a poorly understood disease.

Authors:  William M Weathers; Erik M Wolfswinkel; Daniel A Hatef; Edward I Lee; Larry H Hollier; Rodger H Brown
Journal:  Can J Plast Surg       Date:  2013

Review 7.  Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

Authors:  Naoko Tsuyama; Kana Sakamoto; Seiji Sakata; Akito Dobashi; Kengo Takeuchi
Journal:  J Clin Exp Hematop       Date:  2017

Review 8.  Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Joseph D Tario; Paul K Wallace
Journal:  Clin Lab Med       Date:  2017-12       Impact factor: 1.935

Review 9.  Update on the World Health Organization classification of peripheral T-cell lymphomas.

Authors:  Hilary M O'Leary; Kerry J Savage
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

10.  Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma.

Authors:  K Pulford; B Falini; J Cordell; A Rosenwald; G Ott; H K Müller-Hermelink; K A MacLennan; L Lamant; A Carbone; E Campo; D Y Mason
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.